Cat. No. 4646
Alternative Name: GF 120918
Chemical Name: N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-
Biological ActivityP-glycoprotein (P-gp/ABCG1) inhibitor. Blocks P-gp-mediated multidrug resistance (MDR) of the cytotoxic drugs doxorubicin (Cat. No. 2252) and vincristine (Cat. No. 1257) in CHRC5 cells. Also inhibits breast cancer resistance protein (BCRP/ABCG2). Orally active.
Licensing InformationSold for research purposes under agreement from GlaxoSmithKline.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Hyafil et al (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53 4595. PMID: 8402633.
Myer et al (1999) The chemosensitizing potential of GF120918 is independent of the magnitude of P-glycoprotein-mediated resistance to conventional chemotherapeutic agents in a small cell lung cancer line. Oncol Rep. 6 217. PMID: 9864431.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Elacridar hydrochloride, supplier, GF120918, P-glycoprotein, P-gp, inhibitors, multidrug, resistance, MDR, BCRP, ABCG1, ABCG2, ABCB1
Find multiple products by catalog number
June 28 - July 3, 2014